Proteasome inhibitors impair RANKL‐induced NF‐κB activity in osteoclast‐like cells via disruption of p62, TRAF6, CYLD, and IκBα signaling cascades
- 13 April 2009
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 220 (2) , 450-459
Abstract
Proteasome inhibitors represent a promising therapy for the treatment of relapsed and/or refractory multiple myeloma, a disease that is concomitant with osteolysis and enhanced osteoclast formation. While blockade of the proteosome pathway has been recently shown to influence osteoclast formation and function, the precise molecular cascade underlying these effects is presently unclear. Here, we provide evidence that proteasome inhibitors directly impair osteoclast formation and function via the disruption of key RANK‐mediated signaling cascades. Disruption of the proteosome pathway using selective inhibitors (MG‐132, MG‐115, and epoxomicin) resulted in the accumulation of p62 and CYLD, and altered the subcellular targeting and distribution of p62 and TRAF6 in osteoclast‐like cells. Proteosome inhibition also blocked RANKL‐induced NF‐κB activation, IκBα degradation and nuclear translocation of p65. The disruption in RANK‐signaling correlated dose‐dependently with an impairment in osteoclastogenesis, with relative potency epoxomicin > MG‐132 > MG‐115 based on equimolar concentrations. In addition, these inhibitors were found to impact osteoclastic microtubule organization and attenuate bone resorption. Based on these data we propose that deregulation of key RANK‐mediated signaling cascades (p62, TRAF6, CYLD, and IκBα) underscores proteasome‐mediated inhibition of osteolytic bone conditions. J. Cell. Physiol. 220: 450–459, 2009.Keywords
This publication has 43 references indexed in Scilit:
- Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in miceJournal of Clinical Investigation, 2008
- Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB–regulated gene productsBlood, 2007
- Osteoclasts: What Do They Do and How Do They Do It?The American Journal of Pathology, 2007
- A novel proteasome inhibitor NPI-0052 as an anticancer therapyBritish Journal of Cancer, 2006
- Calcineurin/NFAT Signaling in Osteoblasts Regulates Bone MassDevelopmental Cell, 2006
- Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targetingCell Death & Differentiation, 2005
- Proteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochemical and Biophysical Research Communications, 2005
- Osteoclast differentiation and activationNature, 2003
- Effects of Bafilomycin A1: An inhibitor of vacuolar H (+)‐ATPases on endocytosis and apoptosis in RAW cells and RAW cell‐derived osteoclastsJournal of Cellular Biochemistry, 2003
- Ubiquitin-Binding Protein p62 Expression Is Induced during Apoptosis and Proteasomal Inhibition in Neuronal CellsBiochemical and Biophysical Research Communications, 2001